The alpha-synuclein Preformed Fibrils (PFF) model is a powerful experimental system for studying Parkinson's disease (PD) and related α-synucleinopathies. Unlike transgenic models that overexpress mutant protein, the PFF model exploits the prion-like property of α-synuclein to induce aggregation of endogenous protein.
The PFF model is based on the self-propagating nature of misfolded α-synuclein:
- Seeding: Exogenous synthetic α-synuclein fibrils (PFF) are internalized by neurons
- Template-directed misfolding: PFF serve as templates for endogenous alpha-synuclein to adopt the β-sheet conformation
- Oligomerization: Initial soluble oligomers form, then mature into insoluble fibrils
- Propagation: Aggregated species can transmit between connected neurons
- Endocytosis: PFF enter cells via clathrin-mediated endocytosis
- Autophagy: Both macroautophagy and chaperone-mediated autophagy process aggregates
- Tubulin polymerization: PFF transport along microtubules to the soma
- Synaptic transmission: Inter-neuronal transfer via synaptic vesicles
| Route |
Target |
Typical Dose |
Timeline |
| Intranigral |
Substantia nigra |
5-10 μg PFF |
4-6 weeks |
| Intrastriatal |
Striatum |
5-10 μg PFF |
6-8 weeks |
| Intramuscular |
Peripheral muscle |
50-100 μg PFF |
12-16 weeks |
| Intranasal |
Olfactory bulb |
10-20 μg PFF |
8-12 weeks |
¶ Species and Strain Considerations
- C57BL/6J: Most commonly used strain, moderate sensitivity
- BALB/c: More susceptible to α-synuclein pathology
- Rat: Larger brain volume allows detailed circuit mapping
- pSer129 phosphorylation: Majority of inclusions are phosphorylated at Ser129 (a key pathological hallmark)
- Lewy body-like inclusions: Cytoplasmic inclusions with characteristic morphology
- Neurite pathology: Dystrophic neurites containing α-synuclein aggregates
- Progressive spread: Pathology propagates along neuroanatomically connected pathways
- Dopaminergic neuron loss: 30-50% loss in substantia nigra pars compacta by 6 months
- Striatal terminal degeneration: Dopaminergic terminals degenerate before cell bodies
- Progressive motor deficits: Rotarod, cylinder test, gait analysis deficits
- Microglial activation: Proliferative response around inclusion-bearing neurons
- Astrocyte reactivity: Progressive astrocytosis in affected regions
- Cytokine release: TNF-α, IL-1β, IL-6 elevated in brain and CSF
The PFF model tests interventions at multiple points in the aggregation cascade:
- Aggregation inhibitors: Small molecules preventing oligomer/fibril formation
- Anti-α-synuclein antibodies: Passive immunotherapy (e.g., prasinezumab)
- Autophagy enhancers: Compounds promoting aggregate clearance (e.g., trehalose)
- Microglial modulators: Targeting neuroinflammation
- pSer129 in CSF: Pharmacodynamic marker for anti-α-synuclein therapies
- PET tracers: Imaging agents targeting α-synuclein aggregates (in development)
- Blood biomarkers: Neurofilament light chain (NfL) as neurodegeneration marker
- Propagation mechanisms: Identifying genes and pathways governing inter-neuronal spread
- Strain diversity: Different α-synuclein strains produce distinct pathology patterns
- Cell-to-cell transmission: Viral vector approaches to trace connectivity
¶ Advantages and Limitations
- Endogenous protein: Uses natural α-synuclein levels, not overexpression
- Sporadic-like pathology: Pathogenesis resembles idiopathic PD more closely than transgenic models
- Controllable timing: Defined inoculation point allows precise temporal studies
- Strain flexibility: Different PFF preparations can model distinct α-synucleinopathies (PD, MSA, DLB)
- Surgical procedure: Requires stereotactic injection, adding variability
- Incomplete penetration: Not all inoculated animals develop robust pathology
- Acute induction: Rapid pathology doesn't fully model the chronic progression of sporadic PD
- Technical complexity: PFF preparation and characterization requires expertise
- Luk et al., 2012 - Induction of Lewy body-like pathology in mice
- Volpicelli-Daley et al., 2014 - How to build a Lewy body
- Masuda-Suzukake et al., 2013 - Prion-like spreading of α-synuclein
- Oueslati, 2020 - Implication of α-synuclein aggregation in PD pathogenesis
- Patterson et al., 2019 - Neuropathological assessment of the PFF model